Fate Therapeutics 3Q 2026: Revenue $0, EPS ($0.25) — 10-Q Summary
Fate Therapeutics reported no revenue in 3Q 2026, down from $1.74M a year earlier, due to completed performance obligations under its Ono agreement. Net loss narrowed to $30.69M from $32.25M, with lower R&D and G&A expenses. The company initiated a Phase 2 trial for FT819 and expects $139.1M in cash to fund operations for at least 12 months.
How this was made

The 30-second read
Why it matters
The earnings release provides fresh data on cash runway and trial progress, essential for valuation models.
Market read
First‑time disclosure of Q3 2026 results for a small‑cap biotech, influencing short‑term price action and sector sentiment.
What to watch
Potential upcoming collaborations or pipeline milestones not disclosed may offset the revenue shortfall.
Background
Fate Therapeutics filed its 10‑Q for Q3 2026, reporting the completion of its Ono collaboration obligations and initiating a Phase 2 trial for lupus nephritis.
Ticker impact
Fate Therapeutics disclosed its 3Q 2026 results with zero collaboration revenue and a narrowed net loss.
likely pressure as the market prices in zero revenue and ongoing loss.
Zero collaboration revenue signals reduced near‑term cash flow; despite lower expenses, the loss remains sizable.
Market effects
Biotech sector may see modest sentiment dip as a peer reports no revenue.
US biotech investors could adjust exposure in the short term.
Limited to investors tracking small‑cap biotech earnings.
Counterpoint
The loss narrowing and expense cuts could be seen as a positive operational trend.
Key entities
- companyFate Therapeutics Inc.
US‑listed biotech company (ticker FATE).
- partnerOno Pharmaceutical
Collaborator whose agreement obligations were fulfilled.